

Request for Prior Authorization ACUTE MIGRAINE TREATMENTS

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at **844-512-9004**.

Provider Help Desk: **800-454-3730**

1. Patient information

Patient name: _____

Patient ID #: _____

Patient DOB: _____

Date of Rx: _____

Patient phone #: _____

Patient email address: _____

2. Physician information

Prescribing physician: _____

Physician address: _____

Physician phone #: _____

Physician fax #: _____

Physician specialty: _____

Physician DEA: _____

Physician NPI #: _____

Physician email address: _____

3. Medication

4. Strength

5. Directions

6. Quantity per 30 days

_____	_____	_____	Specify: _____
-------	-------	-------	----------------

7. Diagnosis: _____

8. **Approval criteria:** (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

No prior authorization (PA) is required for preferred acute migraine treatments, as indicated on the Preferred Drug List (PDL). PA is required for acute migraine treatments under the following conditions: 1) A diagnosis of acute migraine; and 2) Patient meets the FDA approved age for requested agent; and 3) For preferred acute migraine treatments where PA is required, as indicated on the PDL, documentation of previous trials and therapy failures with two preferred agents that do not require PA; and/or 4) For nonpreferred acute migraine treatments, documentation of previous trials and therapy failures with two preferred agents that do not require PA. Requests for non-preferred CGRP inhibitors will also require documentation of a trial and therapy failure with a preferred CGRP inhibitor; and/or 5) For quantities exceeding the established quantity limit for each agent, documentation of current prophylactic therapy or documentation of previous trials and therapy failures with two different prophylactic medications; and/or 6) For non-preferred combination products, documentation of separate trials and therapy failures with the individual ingredients, in addition to the above criteria for preferred or non-preferred acute migraine treatments requiring PA. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred 5-HT1- Receptor Agonists
(PA required after 12 doses in 30 days)

- | | |
|--|--|
| <input type="checkbox"/> Imitrex NS | <input type="checkbox"/> Sumatriptan Inj |
| <input type="checkbox"/> Naratriptan | <input type="checkbox"/> Sumatriptan NS |
| <input type="checkbox"/> Rizatriptan ODT | <input type="checkbox"/> Sumatriptan Tablets |
| <input type="checkbox"/> Rizatriptan Tablets | <input type="checkbox"/> Zolmitriptan Tabs |

Non- Preferred 5-HT-1 Receptor Agonists
(PA required from Day 1)

- | | |
|---|---|
| <input type="checkbox"/> Almotriptan | <input type="checkbox"/> Reyvow |
| <input type="checkbox"/> Amerge | <input type="checkbox"/> Sumansetron |
| <input type="checkbox"/> Eletriptan | <input type="checkbox"/> Sumatriptan-Naproxen |
| <input type="checkbox"/> Frova | <input type="checkbox"/> Tosymra |
| <input type="checkbox"/> Frovatriptan | <input type="checkbox"/> Treximet |
| <input type="checkbox"/> Imitrex Inj/Tabs | <input type="checkbox"/> Zembrace |
| <input type="checkbox"/> Maxalt | <input type="checkbox"/> Zolmitriptan NS |
| <input type="checkbox"/> Maxalt MLT | <input type="checkbox"/> Zomig NS |
| <input type="checkbox"/> Onzetra Xsail | <input type="checkbox"/> Zomig Tabs |
| <input type="checkbox"/> Relpax | <input type="checkbox"/> Zomig ZMT |

Preferred CGRP Inhibitors
(PA required)

- Nurtec (Quantity limit 15 doses per 30 days)

Non-Preferred CGRP Inhibitors
(PA required)

- Ubrelvy

Please document the current prophylactic therapy or 2 previous trials and therapy failures with two different prophylactic medications including drug names, strength, exact date ranges and failure reasons:

For Preferred Agents Requiring PA: document trials with two preferred agents that do not require PA

Preferred Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Preferred Trial 2: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

For Non-Preferred Agents Requiring PA: document trials with two preferred agents that do not require PA and a preferred GGRP inhibitor trial, if applicable

Preferred Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Preferred Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Preferred CGRP Inhibitor Trial: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

For quantities exceeding the established quantity limit: document current prophylactic therapy or previous trials and therapy failures with two different prophylactic medications

Preferred Prophylactic Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Preferred Prophylactic Trial 2: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

For Non-Preferred Combination Products: document trials and therapy failures with the individual ingredients (in addition to above criteria for preferred or non-preferred treatments requiring PA)

Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Medical or contraindication reason to override trial requirements: _____

Reason for use of Non-Preferred drug requiring prior approval: _____

Other medical conditions to consider: _____

Attach lab results and other documentation as necessary.

9. Physician signature

Prescriber or authorized signature

***MUST MATCH PRESCRIBER LISTED ABOVE**

Date

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

IMPORTANT NOTE: *In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.*